Abstract:Opioids are highly effective analgesics, however, their therapeutic use is limited by adverse effects that include respiratory depression, dependence, and tolerance. Inflammation has been implicated as a significant driver for the development of tolerance to opioids. Recent studies show that chronic morphine in mice results in gut microbial dysbiosis and inflammation in the colon. In the present study, we examined whether colonic inflammation results in tolerance to the antinociceptive effects of morphine. Colonic inflammation was induced in mice by intrarectal administration of 2,4,6-trinitro-benzene sulfonic acid. The development of antinociceptive tolerance was determined by warm-water tail-immersion assay in mice implanted with 25-, 50-, or 75-mg morphine pellet. Colonic inflammation significantly enhanced the rate at which tolerance developed in each cohort of chronic morphine-treated mice. At the lowest dose of morphine pellet (25 mg), antinociceptive tolerance only developed in the presence of colonic inflammation, whereas in 50- and 75-mg pelleted mice, tolerance developed faster in the inflamed animals than in the noninflamed mice. The enhanced antinociceptive tolerance was attenuated with daily administration of peripheral opioid receptor antagonist, 6 beta-N-heterocyclic-substituted naltrexamine derivative 17-cyclopropyInnethyl-3,14 beta-dihydroxy-4,5 alpha-epoxy-6 beta-[(4'pyridyl) acetamido]nnorphinan (NAP)], irrespective of colonic inflammation. Collectively, these findings show that the rate of tolerance to morphine antinociception is exaggerated in the presence of colonic inflammation, and tolerance is prevented by a peripheral mu-opioid receptor antagonist. These studies suggest a peripheral component to the development of antinociceptive tolerance to opioids. Furthermore, peripherally selective opioid antagonists may be useful adjuncts in opioid-based pain management. SIGNIFICANCE STATEMENT This study supports the notion that inflammation influences the development of antinociceptive tolerance to chronic morphine exposure. We found that, in the presence of colonic inflammation, the rate of development of tolerance to the antinociceptive effects of morphine increased. We also found that treatment with a peripheral opioid receptor antagonist prevented morphine antinociceptive tolerance. Increasing opioid intake during an inflammatory state would result in decreased analgesia and enhanced analgesic tolerance, which puts patients with inflammatory bowel diseases, inflammatory joint diseases, and sickle cell anemia at risk for heavy opioid use.

Minocycline Can Delay the Development of Morphine Tolerance, but Cannot Reverse Existing Tolerance in the Maintenance Period of Neuropathic Pain in Rats

A Novel Role of Minocycline: Attenuating Morphine Antinociceptive Tolerance by Inhibition of P38 MAPK in the Activated Spinal Microglia

Experimental Colitis Enhances the Rate of Antinociceptive Tolerance to Morphine Via Peripheral Opioid Receptors

Blockade of Peripheral Nociceptive Signal Input Relieves the Formation of Spinal Central Sensitization and Retains Morphine Efficacy in a Neuropathic Pain Rat Model.

Minocycline Attenuates Mechanical Allodynia and Expression of Spinal NMDA Receptor 1 Subunit in Rat Neuropathic Pain Model

Microglial TLR4-induced TAK1 phosphorylation and NLRP3 activation mediates neuroinflammation and contributes to chronic morphine-induced antinociceptive tolerance

Potential Role of CXCL10/CXCR3 Signaling in the Development of Morphine Tolerance in Periaqueductal Gray

Spinal TLR4/P2X7 Receptor-Dependent NLRP3 Inflammasome Activation Contributes to the Development of Tolerance to Morphine-Induced Antinociception

Suppressing HMGB1-TLR4-Mediated Neuroinflammation Alleviates Morphine Tolerance via Inhibiting AMPK-HO-1 Pathway in The Spinal Cord of Mice

Effect of Metabotropic Glutamate 5 Receptor Antagonists on Morphine Efficacy and Tolerance in Rats with Neuropathic Pain.

Activation of P38 Mitogen-Activated Protein Kinase in Spinal Microglia Mediates Morphine Antinociceptive Tolerance

Chronic Morphine Treatment Increased the Expression of Myeloid Differentiation Primary Response Protein 88 in Rat Spinal Cord

Spinal MCP-1 Contributes to the Development of Morphine Antinociceptive Tolerance in Rats.

Inhibition of Neuronal Nitric Oxide Synthase Antagonizes Morphine Antinociceptive Tolerance by Decreasing Activation of P38 MAPK in the Spinal Microglia.

Involvement Of Spinal Microglial P2x(7) Receptor In Generation Of Tolerance To Morphine Analgesia In Rats

MicroRNA-146a Attenuates the Development of Morphine Analgesic Tolerance in a Rat Model

Comparison of Morphine and Endomorphin Analog ZH853 for Tolerance and Immunomodulation in a Rat Model of Neuropathic Pain

Activation of spinal PDGFRβ in microglia promotes neuronal autophagy via p38 MAPK pathway in morphine-tolerant rats

Cathepsin S in the Spinal Microglia Facilitates Morphine-Induced Antinociceptive Tolerance in Rats

Regulatory Mechanisms and Therapeutic Potential of Microglial Inhibitors in Neuropathic Pain and Morphine Tolerance

Increased Glutamate Synaptic Transmission in the Nucleus Raphe Magnus Neurons from Morphine-Tolerant Rats